Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been given a consensus rating of “Moderate Buy” by the five research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.50.

Several equities analysts have recently commented on AMRX shares. JPMorgan Chase & Co. upped their target price on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 target price (up from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $12.59 on Friday. The firm has a market cap of $3.96 billion, a price-to-earnings ratio of 1,259.86 and a beta of 1.21. Amneal Pharmaceuticals has a 1-year low of $6.68 and a 1-year high of $12.68. The firm has a fifty day moving average price of $10.81 and a two-hundred day moving average price of $9.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. The business had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the sale, the director owned 291,029 shares in the company, valued at approximately $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Nikita Shah sold 131,856 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total value of $1,571,723.52. Following the transaction, the executive vice president owned 146,403 shares of the company’s stock, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 231,856 shares of company stock worth $2,743,724. Corporate insiders own 26.56% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Comerica Bank grew its stake in shares of Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Amneal Pharmaceuticals in the first quarter worth about $31,000. Exchange Traded Concepts LLC acquired a new stake in Amneal Pharmaceuticals in the third quarter worth about $31,000. Focus Partners Wealth bought a new position in Amneal Pharmaceuticals in the 3rd quarter valued at about $42,000. Finally, Advisory Services Network LLC bought a new position in Amneal Pharmaceuticals in the 3rd quarter valued at about $50,000. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.